Search Results

Oncoceutics, a clinical-stage drug discovery and development company, commemorates National Childhood Cancer Awareness Month this September and reiterates its support for children and all those affected by childhood cancer.

Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health (NIH) involving its imipridone family of anti-cancer compounds

Oncoceutics, Inc., announced a collaboration with the National Cancer Institute funded Pediatric Preclinical Testing Consortium to enable tumor type selection for ONC201 clinical trials in pediatric oncology beyond diffuse midline gliomas.

Oncoceutics announced today that Michael Chiarella, an industry veteran with more than 20 years’ experience at a number of large and small biotech companies, is joining the company as Vice President, Clinical Operations

Philadelphia, PA – Oncoceutics, Inc., announced that it has signed an exclusive, world-wide license for US patent #10,239,877, entitled “Pharmacophore for trail induction”, from The Scripps Research Institute, covering the composition of matter of ONC201 as well as other molecules in the imipridone family.

Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million

Oncoceutics announced the appointment of Minesh Mehta, MD, FASTRO, to the company’s Board of Directors.

Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for ONC206, allowing the first-in-human trial of the compound. ONC206 is the first of the family of drug candidates, which we call “imipridones”, that possess the same core chemical structure as ONC201.

Oncoceutics announced that the USPTO issued patent #9,845,324, providing the company with composition of matter protection for ONC212 and several additional small molecules derived from Oncoceutics’ lead compound ONC201.

Oncoceutics and Calvert Research, LLC announced that the two companies have entered into a second product development and investment partnership agreement, this time to further develop and enable the submission of an IND application for ONC206, Oncoceutics’ next generation molecule.